Browsing by Author "Sedef, Ali Murat"

Now showing 1 - 4 of 4

Clinicohistopathological features and treatment outcomes of neuroendocrine tumors: a single center experience
(CUKUROVA UNIV, FAC MEDICINE, 2018-01-01) Sedef, Ali Murat; Kose, Fatih; Sumbul, Ahmet Taner; Mertsoylu, Huseyin; Besen, Ali Ayberk; Sezer, Ahmet; Ozyilkan, Ozgur; Abali, Huseyin
Purpose: Tumor and patient characteristics of neuroendocrine tumors (NET) significantly change between geographical locations that probably induced by environmental and genetic factors throughout the world. Therefore, reporting single center experience may help clarifying epidemiological view and improving decision-making process. Materials and Methods: We performed retrospective analysis of 115 patients of NETs those who followed by Baskent University, department of Medical Oncology and department of General Surgery to record patients and tumors characteristics, treatment modalities, survival rates, and prognostic factors. Results: Median overall survival (OS) time for all group and localized NETs were 44 and 24 months, respectively. Most common primary site was found as gastrointestinal system and then pancreatic region. Curative surgical resection rate was 46\% and 8.5\% of patients presented with carcinoid syndrome. Liver metastasis was far the most common metastatic site compared to lung, bone, and lymph node metastasis. Over 70 percent of patients were treated with chemotherapy and somatostatin analogs. Conclusion: Patients with higher grade, male gender, and advanced age (>65 years old) had poor survival rate. However, relatively low number of patients and less usage of (<10\%) of new treatment modalities created limitations for producing future directions from our study.
Concurrent chemoradiotherapy with weekly carboplatin and paclitaxel may be a feasible option in inoperable stage III non-small cell lung cancer: a single center experience
(CUKUROVA UNIV, FAC MEDICINE, 2019-01-01) Calikusu, Zuleyha; Sedef, Ali Murat; Saltaoglu, Pinar
Purpose: Concurrent chemoradiotherapy (CCRT) is a standard treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC). An optimal chemotherapy regimen with concurrent thoracic radiotherapy is not known. In this study, we investigated the efficacy and toxicity of CCRT with carboplatin {[}area under curve (AUC) 2] and paclitaxel (80 mg/m(2)) during CCRT. Materials and Methods: We performed a retrospective survival analysis using medical records of 40 patients with inoperable stage III NSCLC that were treated with concurrent chemoradiotherapy with carboplatin-paclitaxel (AUC 2, 60 mg/m2). Results: The most common histopathology was adenocarcinoma, which was diagnosed in 18 patients (45\%). There were 12 stage IIIA patients (30\%) and 28 stage IIIB patients (70\%). The median follow-up time was 22.5 months {[}95\% confidence interval (CI), 2.9-72.2]. Median disease-free survival (DFS) and overall survival (OS) were 22.5 months (95\% CI, 18.1-27.0) and 53.5 months (95\% CI, 23.5-82.8). Grade 3-4 hematological and non-hematological toxicities were seen in 8 (20\%) and 5 (12.5\%) patients, respectively. Conclusion: This study showed that CCRT with weekly carboplatin-paclitaxel provides similar outcomes to cases in the literature and the regimen seems to be feasible with a low rate of grade 3-4 toxicity during CCRT of non operable stage III NSCLC. Keywords: Carboplatin, non-small cell lung cancer, chemoradiotherapy, paclitaxel
Prognostic value of basal neutrophil lymphocyte ratio in patients with extensive stage small cell lung cancer
(CUKUROVA UNIV, FAC MEDICINE, 2018-01-01) Sedef, Ali Murat; Calikusu, Zuleyha; Bahceci, Aykut; Gokcay, Serkan; Besen, Ali Ayberk; Sumbul, Ahmet Taner
Purpose: The neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and lymphocytopenia are markers of poor prognosis in lung cancer patients. The aim of this trial is evaluate the prognostic significance of basal NLR, PLR and lymphocytopenia in patients with extensive stage (ES) small cell lung cancer(SCLC). Materials and Methods: This study was designed as a hospital-based retrospective observational case-series study. A total of 117 patients with extensive stage small cell lung cancer have been treated at four different oncology centers in Turkey between 2011 and 2017. Laboratory results and demographic data were collected. Results: The median follow-up time was 12 months and 95 (81\%) patients died. Progression-free survival (PFS) and overall survival (OS) were estimated, respectively, as 8 and 13 months. 65 (55.6 \%) patients had complete response at the end of first line platin-etoposide combination treatment. The cut-off value for NLR and PLR were determined for whole group and patients were dichotomized into high (>= 3.28) and low (<3.28) NLR groups and high (>= 139.8) and low (< 139.8) PLR groups.. Median OS was lower in patients who had high neutrophil lymphocyte ratio (NLR) (14 versus 12 months respectively). Conclusion: This study showed that basal NLR may have prognostic biological value in patients with ES SCLC treated with cisplatin + etoposide.
The Prognostic Significance of Complete Response Rates in Patients with Extensive Stage Small Cell Lung Cancer
(KARE PUBL, 2019-01-01) Sedef, Ali Murat; Calikusu, Zuleyha; Bahceci, Aykut; Gokcay, Serkan; Sumbul, Ahmet Taner
OBJECTIVE Small cell lung cancer (SCLC) is the most aggressive type of lung cancer. Platinum-etoposide chemotherapy combination is used as first line treatment. The aim of this trial is evaluate the effect of complete response rates and clinical features in patients with extensive stage (ES) SCLC. METHODS In this retrospective study, a total of 117 patients from four different oncology centers in Turkey between 2011 and 2017 were divided into 2 groups, namely, patients with complete response (group 1) and those with no complete response (group 2) after platin-etoposide combination therapy. RESULTS The median age of the patients was 61 (range 38-81) years. The median follow-up time was 12 months and 95 (81\%) patients died. Progression-free survival (PFS) and overall survival (OS) were estimated, respectively, as 8 and 13 months. Overall survival of group 1 patients was statistically significantly better than the group 2 (16 versus 10 months respectively and p=0.00). The overall survival of patients who had late recurrent disease (>6 mo.) was statistically significantly better than the early ones (<6 mo) (19 versus 14 months respectively and p=0,008). CONCLUSION Complete response and recurrent free time were the prognostic factors for ES SCLC patients in our study